Type 1 diabetes (T1D) management requires constant vigilance: blood glucose monitoring, insulin dosing, and dietary adjustments. The artificial pancreas (AP) — an automated insulin delivery system — promises to ease this burden by mimicking the pancreas’s function. However, while AP systems have transformed care in high-income countries, their complexity and cost have largely excluded the 1.5 million people with T1D living in low- and middle-income countries. This article examines the components of AP technology, the unique barriers to its adoption in resource-limited settings, and the promising opportunities for making closed-loop therapy accessible worldwide.

Key Components of an Artificial Pancreas

An artificial pancreas integrates three essential elements: a continuous glucose monitor (CGM), an insulin pump, and a control algorithm. The CGM measures interstitial glucose every one to five minutes, transmitting data wirelessly to the algorithm, which calculates the optimal insulin dose and commands the pump to deliver it. Modern hybrid closed-loop systems still require user meal announcements and occasional calibrations, but fully automated bi-hormonal systems (delivering both insulin and glucagon) are under investigation. The algorithm — often a proportional-integral-derivative or model predictive control — must keep glucose within a target range of 70–180 mg/dL, minimizing both hypoglycemia and hyperglycemia.

Commercial systems like the Medtronic MiniMed 780G, Tandem Control‑IQ, and Omnipod 5 have demonstrated consistent improvement in time-in-range by 10–15 percentage points over conventional pump therapy, with reductions in HbA1c and severe hypoglycemia. Yet all rely on proprietary CGMs, pumps, and algorithms, with upfront costs exceeding $5,000–$10,000 and monthly supplies of sensors and infusion sets adding hundreds of dollars. They also require stable electricity, internet connectivity for updates and remote monitoring, and specialized clinicians for training and troubleshooting. These prerequisites make them nearly impossible to deploy in settings where power is unreliable, internet is scarce, and endocrinologists are rare.

Unique Challenges in Low‑Resource Settings

Inadequate Infrastructure and Unreliable Power

The most fundamental barrier is the lack of reliable electricity. Insulin pumps and CGM receivers are battery-powered; they require regular charging or battery replacement. In sub-Saharan Africa, fewer than 50% of households have access to electricity, and even where power is available, voltage fluctuations can damage electronics. Cloud-based data sharing, software updates, and telemedicine visits — essential for initiating and maintaining AP therapy — demand stable internet, which is often patchy or nonexistent. A power outage during the night could lead to pump failure, missed insulin delivery, and diabetic ketoacidosis. Without these basics, an AP system cannot function safely or be sustained over time. For example, a pilot project in rural Rwanda using a modified closed-loop system had to suspend operations after repeated power interruptions corrupted the pump’s firmware.

Prohibitively High Costs

Even where infrastructure exists, the cost of AP technology is prohibitive. In the United States, the upfront system price ranges from $5,000 to $15,000, with monthly sensor and pump supplies costing $300–$600. In low-income countries, where annual per capita health spending is often less than $100, these figures are utterly unattainable. Insulin itself remains unaffordable: a 2021 The Lancet study estimated that one in four people with T1D in low-income countries cannot afford even basic insulin. Adding an AP system without substantial price reductions, subsidies, or innovative financing would deepen global health inequity. Governments and donors must negotiate bulk purchasing, impose price caps, or finance local manufacturing to bring costs down. For instance, the Insulin Access Initiative has secured reduced insulin prices for several African nations; a similar mechanism for CGM sensors and pumps could be explored.

Critical Shortage of Specialized Healthcare Providers

Artificial pancreas systems require training and supervision by endocrinologists or certified diabetes educators who understand pump therapy, CGM interpretation, and algorithm adjustment. Yet many low-resource countries have fewer than one endocrinologist per million people. Diabetes care is often managed by general practitioners, nurses, or clinical officers with minimal exposure to pump technology. This shortage creates a vicious cycle: without local expertise, AP research cannot be conducted, and without research, expertise never develops. A 2022 survey in East Africa found that only 3% of diabetes clinics offered insulin pump therapy, and none had experience with closed-loop systems. Task-sharing with trained community health workers (CHWs) and nurse-led models, supported by remote specialist supervision, could help bridge this gap, but rigorous safety protocols must be established.

Cultural, Educational, and Language Barriers

Even when infrastructure and cost are addressed, cultural perceptions and low health literacy impede adoption. In some communities, wearing a visible medical device may be stigmatized, or trusting a machine to deliver a life-sustaining hormone may meet with skepticism. Patients may lack the educational background to operate the system, respond to alarms, or recognize early signs of pump failure. Language barriers complicate the translation of user interfaces and educational materials. Additionally, diabetes is sometimes viewed as a “rich person’s disease” or attributed to supernatural causes, discouraging people from seeking advanced care. These sociocultural factors must be addressed through community engagement, culturally tailored education, and involvement of local leaders. For example, a project in Malawi co-designed illustrated instruction booklets in the local language and used village health volunteers to demonstrate device use, resulting in higher retention rates.

Regulatory and Supply Chain Hurdles

Regulatory approval pathways differ across countries, and many low-resource nations lack the infrastructure to review novel AP systems. Even after approval, fragile supply chains for consumables — sensors, reservoirs, batteries — pose major risks. Delays at borders, lack of cold-chain storage for insulin, and counterfeit products are common. Research studies requiring a steady, uninterrupted supply of devices face high attrition and data loss. A pilot AP trial in India was delayed six months because customs held shipment of CGM sensors, and those that arrived had expired by the time they were distributed. Establishing regional regulatory harmonization (e.g., through the African Medicines Agency) and strengthening local supply chains are essential for both research and eventual scale-up.

Opportunities for Innovation and Impact

Low‑Cost, Simplified System Designs

Rather than attempting to replicate high-end commercial systems, researchers can design purpose-built solutions that scale down features while preserving safety and efficacy. This includes using low-cost, strip-based glucose monitors instead of CGMs (though with reduced frequency), developing patch pumps with minimal electronics, or creating open-source algorithms that run on repurposed smartphones. The OpenAPS and Loop communities have demonstrated that do-it-yourself closed-loop systems can be built from off-the-shelf components for a fraction of the cost. Adapting these approaches for local manufacturing and regulatory contexts could dramatically lower barriers. The Tidepool Loop initiative aims to create an FDA-cleared interoperable closed-loop system, reducing reliance on single-vendor ecosystems. For low-resource settings, a simplified system could use a reusable smartphone app as the algorithm, a Bluetooth-enabled insulin pen instead of a pump, and a low-cost CGM that lasts two weeks — targeting a per-patient cost under $500 per year.

Leveraging Mobile Technology

Mobile phone penetration exceeds 80% in many low-resource settings, even when other infrastructure is weak. Smartphones can serve as the algorithmic hub of an AP system, processing CGM data via an app, communicating with a pump over Bluetooth, and uploading information to cloud servers when internet is available. This reduces hardware costs and allows for over-the-air algorithm updates. Several research groups, such as the Diabetes Reimagined: Enhancing Access through Mobile (DREAM) collaborative, are exploring smartphone-based closed-loop systems in Africa and South Asia. Even basic feature phones can support SMS-based reminders for glucose checks, insulin doses, and device alarms. A 2023 pilot in Uganda used daily SMS messages to improve adherence to CGM wear, with participants reporting high satisfaction and reduced anxiety. Mobile technology also facilitates remote monitoring by healthcare workers, enabling earlier intervention when problems arise.

Community‑Based Care Models

Given the shortage of specialists, successful AP research and deployment must rely on community health workers (CHWs) and task-sharing. CHWs can be trained to assist with device initiation, troubleshooting, and ongoing support under the remote supervision of an endocrinologist via telemedicine. A 2022 pilot study in Kenya demonstrated that nurse-led training for insulin pump therapy was feasible and acceptable, though more data on safety outcomes are needed. Integrating AP technology into existing chronic disease management programs for HIV or hypertension — which already have established healthcare networks, supply chains, and community trust — could accelerate adoption. The NCD Alliance has developed frameworks for integrating diabetes care into primary health systems in low-income countries; these can be adapted for closed-loop technology by adding device-specific modules and protocols.

Global Research Collaborations and Open Science

No single institution or country can solve the AP equity problem alone. International partnerships — between academic centers in the US/Europe and institutions in Africa, Southeast Asia, and Latin America — pool expertise, funding, and data. The JDRF’s Artificial Pancreas Project has catalyzed global research, but more focused initiatives for low-resource contexts are needed. Open-source algorithms (e.g., OpenAPS, Loop), shared clinical protocols, and centralized adverse event reporting systems can reduce duplication and accelerate learning. Collaborations with local Ministries of Health and organizations like the World Health Organization help align research with population health needs. For example, the “AP for All” consortium unites researchers from 12 countries to develop an open-source, low-cost closed-loop platform specifically designed for resource-limited environments. Such collaborations also facilitate capacity building, training local investigators in clinical trial conduct and device maintenance.

Adaptive Clinical Trial Designs

Traditional randomized controlled trials for AP systems require extensive infrastructure, frequent clinic visits, and high data quality that may be unrealistic in low-resource settings. Alternative designs — pragmatic cluster-randomized trials, stepped-wedge designs, or n-of-1 studies — can generate actionable evidence with fewer resources. Real-world data collection via mobile apps and periodic telephone interviews can supplement in-person visits. Regulatory bodies are increasingly accepting evidence from well-designed real-world studies, which could open the door for faster, lower-cost approval pathways. The FDA’s Real‑World Evidence Program provides a framework that could be adopted by national regulators in low-income nations. Furthermore, using Bayesian statistical methods can allow smaller sample sizes and adaptive allocation, reducing study costs while maintaining validity.

Future Directions and Key Considerations

Affordable CGM and Pump Technology

The single largest cost driver for AP systems is the CGM sensor. Efforts to develop lower-cost, factory-calibrated sensors that last two weeks or more and require no finger-stick calibration are underway. Some startups are working on microneedle-array CGM prototypes that can be manufactured for under $10 per sensor. Similarly, insulin pumps with disposable, prefilled cartridges and minimal electronics could drop the pump price below $200. Governments and philanthropic organizations could negotiate bulk purchasing agreements or issue tenders that incentivize manufacturers to enter these markets. The Global Fund model for HIV/AIDS medicines — where pooled procurement and price negotiation drove down antiretroviral costs — could serve as a template for subsidizing AP consumables. Additionally, local production of sensors and pumps in regional hubs (e.g., in Kenya or India) could reduce import duties and supply chain fragility.

Policy and Advocacy

Research alone is not enough; policy changes are needed to ensure access. This includes inclusion of AP devices on the WHO Essential Medicines List (which already includes insulin and some CGM components), tariff reductions on electronics and medical devices, and creation of national diabetes registries that track outcomes. Advocacy groups like the International Diabetes Federation and local patient organizations can raise awareness and lobby for funding from ministries of health and international donors. Training programs for healthcare workers must be integrated into medical and nursing curricula, and telemedicine regulations should be updated to allow cross-border device support and remote prescribing. In 2023, the WHO’s Global Diabetes Compact recognized the need for affordable diabetes technology, signaling political momentum that could drive concrete action. Researchers and clinicians should engage with these policy processes to ensure that AP technology is prioritized.

Ethical Considerations and Equity

Conducting research in low-resource settings raises ethical questions about informed consent, data sharing, and the risk of creating a “two-tier” system where only the wealthy benefit. Researchers must engage local communities from the outset, ensuring studies are designed with cultural sensitivity and that participants have genuine agency. Any successful AP solution must be accompanied by a sustainability plan covering maintenance, supply continuity, and eventual transfer of manufacturing capability to local producers. Without these safeguards, even well-intentioned research can inadvertently widen health disparities. A 2022 opinion piece in Nature Medicine argued that equity should be a primary endpoint in AP trials, not an afterthought. Researchers should also ensure that participants have access to the technology after the trial ends, ideally through government or donor-funded programs. Partnerships with local ethical review boards and community advisory boards can help navigate these complex issues.

The path to an affordable, robust artificial pancreas for all is long, but the potential impact is enormous. By recognizing and addressing the specific challenges of low-resource settings — and by seizing opportunities for frugal innovation, mobile integration, and global collaboration — the diabetes community can ensure that closed-loop therapy becomes a realistic option for the many, not just the few. Research conducted today in these settings will not only improve local outcomes but also generate insights that make AP systems more resilient, cost-effective, and user-friendly everywhere. The time to act is now, with a focus on equity, sustainability, and genuine partnership.